SCHEMBL14725911

SCHEMBL14725911

CSc1nc(C)cn2cccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.49
ALDH1A1 P00352 7/20 0.36
KDM4E B2RXH2 6/20 0.36
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
TP53 P04637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 3/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRNA7 P36544 1/20 0.34
HTR3A P46098 1/20 0.34
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8858892 0.82 GRM5 (0.36) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL13153126 0.77 GRM5 (0.54) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL15754794 0.74 GRM5 (0.55) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL18472057 0.71 GRM5 (0.49) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL4562282 0.70 KDM4E (0.34) ALDH1A1KDM4ERAB9ANPSR1HPGD
SCHEMBL13155401 0.68 L3MBTL1 (0.42) MEN1KMT2A
SCHEMBL10143645 0.66 PDE10A (0.38) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL3971488 0.66 NPC1 (0.61) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL27122183 0.66 GRM5 (0.34) GRM5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL15760264 0.64 OPRM1 (0.42) GRM5CHRNA7HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130131057-A1 NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO (ES) 2013-05-23 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A GRM5 4563/4885ALDH1A1 2425/4885KDM4E 2475/4885
US-20130131057-A1 NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS MTOR, PIK3CA, PIK3C2A GRM5 4592/4885ALDH1A1 3580/4885KDM4E 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.